OncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Ca...
April 09 2018 - 8:30AM
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage
biopharmaceutical company focused on discovering and developing
novel anti-cancer therapeutics, today announced that five posters
will be presented at the upcoming American Association for Cancer
Research (AACR) Annual Meeting to be held April 14-18, 2018, in
Chicago. Among the presentations will be preclinical data for
OncoMed’s novel anti-TIGIT (OMP-313M32) immuno-oncology program,
which is currently in a Phase 1a single-agent clinical study.
Preclinical data for OncoMed’s differentiated clinical-stage
GITRL-Fc (OMP-336B11) program will also be featured. In addition,
preclinical immuno-oncology data for OncoMed’s Wnt antagonist
vantictumab (anti-FZD, OMP-18R5) in combination with immune
checkpoint inhibitors will be presented.
Details on the poster presentations are provided below:
Poster 20; Abstract 70: Effect of aging on the
antitumor activity of GITRL-FcSession: Tumor
Biology, Dormancy and Aging: The Influential
MicroenvironmentDate and Time: Sunday Apr 15, 2018
1:00 PM - 5:00 PMLocation: McCormick Place
South, Exhibit Hall A, Poster Section 3
Poster 28; Abstract 1733: Wnt antagonists
synergize with immune checkpoint inhibitors to enhance anti-tumor
responsesSession: Immunology, Immune
Responses to Therapies 2Date and Time: Monday
Apr 16, 2018 8:00 AM - 12:00
PMLocation: McCormick Place South, Exhibit
Hall A, Poster Section 32
Poster 18; Abstract 2726: In vitro functional
activity of OMP-336B11, a GITRL-Fc fusion protein, on primary human
immune cellsSession: Immunology, Immune
Checkpoints 2Date and Time: Monday Apr 16,
2018 1:00 PM - 5:00 PMLocation: McCormick
Place South, Exhibit Hall A, Poster Section 32
Poster 16; Abstract 3826: GITRL-Fc biomarker
and mechanism study: GITRL-Fc reduces Treg frequency in tumors and
requires effector function for inhibition of tumor
growthSession: Immunology, Therapeutic Antibodies,
Including Engineered Antibodies 3Date and Time:
Tuesday Apr 17, 2018 8:00 AM - 12:00
PMLocation: McCormick Place South, Exhibit
Hall A, Poster Section 34
Poster 22; Abstract 5627:
Anti-TIGIT biomarker study: Inhibition of TIGIT induces loss of
Tregs from tumors and requires effector function for tumor growth
inhibition Session: Clinical Research, Therapeutic
Antibodies, Including Engineered Antibodies 4Date and
Time: Wednesday Apr 18, 2018 8:00 AM - 12:00
PMLocation: McCormick Place South, Exhibit
Hall A, Poster Section 28
Following the presentations, the posters will be available on
the Pipeline section of OncoMed’s website, www.oncomed.com.
Additional information on the meeting can be found on the AACR
website www.aacr.org.
About OncoMed PharmaceuticalsOncoMed
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on discovering and developing novel anti-cancer
therapeutics. OncoMed has internally discovered a broad pipeline of
investigational drugs intended to address the fundamental biology
driving cancer's growth, resistance, recurrence and metastasis.
Anti-TIGIT (OMP-313M32), navicixizumab (anti-DLL4/VEGF bispecific,
OMP-305B83), and rosmantuzumab (anti-RSPO3, OMP-131R10) are part of
OncoMed's strategic alliance with Celgene Corporation. OncoMed is
independently developing GITRL-Fc (OMP-336B11), as well as
continuing to pursue new drug discovery research. For further
information about OncoMed Pharmaceuticals, please see
www.oncomed.com.
Investor Relations Contact:
Matthew BeckSolebury Troutmbeck@troutgroup.com(646) 378-2933
ONCOMED PHARMACEUTICALS INC (NASDAQ:OMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
ONCOMED PHARMACEUTICALS INC (NASDAQ:OMED)
Historical Stock Chart
From Apr 2023 to Apr 2024